Jefferies raised their price target on ImmunityBio (IBRX) to $9 from $8 and maintained a buy rating. This move follows the European Medicines Agency granting conditional marketing authorization for Anktiva, their treatment for non-muscle-invasive bladder cancer. The drug is already approved in the US and UK, so this decision expands their commercial reach into the EU. The therapy is designed to be used in combination with BCG.